Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVASARC: Envafolimab with or without Ipilimumab in Advanced UPS/MFS
NCT04480502Phase 2Active, not recruiting
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Dec 2020
- Primary completion
- Oct 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of envafolimab in undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma (MFS), sponsored by TRACON Pharmaceuticals, Inc.. Started Dec 2020; status: active, not recruiting.
02
Drugs
envafolimab
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)myxofibrosarcoma (MFS)
Beyond the preview
Go deeper on NCT04480502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480502.